# A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Study · id `cardio:ct-nct02861534` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02861534](<https://clinicaltrials.gov/study/NCT02861534>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02861534

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5050 participants.

## Technical summary

Registry record NCT02861534. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2019-06-18 (actual). Results posted on 2020-06-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5050 participants (enrolled count; ClinicalTrials.gov record NCT02861534, source copy `cardio:ctgov-nct02861534-2021-11-15`, retrieved 2026-10-26)
- Started: 2016-09-20 (actual) (ClinicalTrials.gov record NCT02861534, source copy `cardio:ctgov-nct02861534-2021-11-15`, retrieved 2026-10-26)
- Primary completion: 2019-06-18 (actual) (ClinicalTrials.gov record NCT02861534, source copy `cardio:ctgov-nct02861534-2021-11-15`, retrieved 2026-10-26)
- Completion: 2019-09-02 (actual) (ClinicalTrials.gov record NCT02861534, source copy `cardio:ctgov-nct02861534-2021-11-15`, retrieved 2026-10-26)
- Results first posted: 2020-06-29 (ClinicalTrials.gov record NCT02861534, source copy `cardio:ctgov-nct02861534-2021-11-15`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02861534-2021-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
- Acronym: VICTORIA
- Condition: Heart Failure
- Condition: Chronic Heart Failure With Reduced Ejection Fraction
- Intervention (Drug): Vericiguat
- Intervention (Drug): Placebo for vericiguat
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Canadian VIGOUR Centre
- Collaborator class: OTHER
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Canadian VIGOUR Centre (`cardio:org-canadian-vigour-centre`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial (`cardio:pubmed-31820546`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction (`cardio:pubmed-32222134`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial (`cardio:pubmed-33185650`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial (`cardio:pubmed-35791083`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat (`cardio:pubmed-36049817`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial (`cardio:pubmed-37331690`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial (`cardio:pubmed-37417824`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial (`cardio:pubmed-37671551`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction (`cardio:pubmed-38363272`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial (`cardio:pubmed-38934967`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6e52b794b563815c8b3f51c2c6f78f14e129cdf520ae48fd13d812c85a90c787
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
